A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

NCT02124668 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Castration-Resistant Prostate Cancer
Prostate Cancer

Interventions

DRUG: Enzalutamide

Sponsor

Astellas Pharma Europe B.V.

Collaborators

[object Object]